Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Variation of the N-Acetyltransferase 2 Gene in a Romanian and a Kyrgyz Population

Sylvia Rabstein, Klaus Unfried, Ulrich Ranft, Thomas Illig, Melanie Kolz, Hans-Peter Rihs, Chinara Mambetova, Mariana Vlad, Thomas Brüning and Beate Pesch
Sylvia Rabstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Unfried
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Ranft
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Illig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Kolz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Rihs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chinara Mambetova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Vlad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Brüning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beate Pesch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-05-0256 Published January 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

As part of a project on environmental disasters in minority populations, this study aimed to evaluate differences in the sequence of N-acetyltransferase 2 (NAT2) as a metabolic susceptibility gene in yet unexplored ethnicities. Eight single nucleotide polymorphisms (SNP) in the NAT2 coding region and a variant in the 3′ flanking region were analyzed in 290 unrelated Kyrgyz and 140 unrelated Romanians by SNP-specific PCR analysis. The variants 341C, 481T, and 803G were less and 857A more prevalent in Kyrgyz (P < 0.0001). The variant at site 857 indicates Asian descent. 282C>T and 590G>A showed no significant variation by ethnicity. 364G>A and 411A>T turned out to be monomorphic. Database comparisons of the NAT2 minor allele frequencies support that Romanians belong to Caucasians and Kyrgyz are in between Caucasians and East Asians. The distributions of predicted haplotypes differed significantly between the two ethnicities where the Kyrgyz showed a higher genetic diversity. The haplotype without mutations was more common in Kyrgyz (40.1% in Kyrgyz, 29.3% in Romanians). Accordingly, the imputed slow acetylator phenotype was less prevalent in Kyrgyz (35.2% versus 51.4% in Romanians). We found pronounced ethnic differences in NAT2 genotypes with yet unknown effect on the health risks for environmental or occupational exposures in minority populations. (Cancer Epidemiol Biomarkers Prev 2006;(15)1:138–41)

  • Arylamine N-acetyltransferase 2
  • single nucleotide polymorphism
  • haplotype
  • phenotype
  • ethnicity

Introduction

The role of susceptibility genes in the development of chronic diseases is an important issue in occupational and environmental medicine. Arylamine N-acetyltransferase 2 (NAT2) catalyzes the addition of an acetyl group from acetyl-CoA to a terminal nitrogen on substrates (1). NAT2 is a gene with a 870-bp coding region mapped to chromosome 8p22. The GenBank accession number X14672 is commonly used as reference sequence (URL: http://www.ncbi.nlm.nih.gov/). As of June 5, 2003, 36 human NAT2 alleles were reported based on variations at 15 nucleotide positions (URL: http://www.louisville.edu/medschool/pharmacology/NAT.html). We further refer to this database as NAT database. An additional single nucleotide polymorphism (SNP) in the 3′ flanking region was documented in the SNP500Cancer database of Cancer Genome Anatomy Project (ref. 2; URL: http://snp500cancer.nci.nih.gov) and in the database of Perlegen Sciences (ref. 3; URL: http://genome.perlegen.com). We further refer to these databases as SNP500 database and Perlegen database. First results of an international project on genetic susceptibility to environmental carcinogens revealed a large variation of allele frequencies in control populations by ethnicity (4). Here, we report on the genetic variation of NAT2 in a European (Romanian) and Central-Asian (Kyrgyz) study population analyzed as a part of the European Commission-funded project “Investigation of the Risk of Cyanide in Gold Leaching on Health and Environment in Central Asia and Central Europe” (IRCYL; ref. 5).

Materials and Methods

Study Population

Unrelated subjects were selected for the analyses of NAT2 gene variants from two population surveys of IRCYL. NAT2 genotypes were obtained from whole blood samples collected with informed consent. The study was approved by the Ethics Committee of the Kyrgyz Medical Academy and by the Romanian Ministry of Health. In total, 140 Romanian and 290 Kyrgyz subjects were included.

Genotyping of NAT2 Variants

Genomic DNA from frozen blood samples was prepared at the Kyrgyz Scientific Center of Haematology (Bishkek, Kyrgyzstan) and the Institute of Public Health (Cluj-Napoca, Romania) using the QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Germany) according to the protocol of the manufacturer. DNA was then shipped to Institut für umweltmedizinische Forschung (Düsseldorf, Germany) and tested for its applicability in PCR assays. NAT2 variants documented as polymorphic in the SNP500 database were selected for genotyping with the MassARRAY system (Sequenom, San Diego, CA; ref. 6). These variant sites comprised two synonymous polymorphisms (282C>T and 481C>T), six nonsynonymous SNPs (341T>C, 364G>A, 411A>T, 590G>A, 803A>G, and 857G>A), and a C>T polymorphism in 3′ untranslated region (rs2552). Two variants (364G>A and 411A>T) turned out to be monomorphic in the IRCYL populations. No assay could be established for the rare polymorphism 191G>A. Genotyping call rates were ≥96.8%.

Statistical Analyses

NAT2 analyses were calculated using SAS 8.02 (Cary, NC). Deviations from Hardy-Weinberg equilibrium were examined with exact tests. The minor allele was defined as the less frequent nucleotide at the polymorphic site for which frequencies are shown with 95% confidence limits. To investigate differences in genotype distributions by χ2 test, we used a Caucasian and a Chinese population from public databases (SNP500 database and Perlegen database). Haplotypes were inferred using PHASE version 2.0.2 based on coding SNPs with positional information (7, 8).

Further information on genotyping and the prediction of haplotypes can be found on the internet (URL: http://www.bgfa.ruhr-uni-bochum.de/specials/NAT2.php).

Results

The distribution of the genotypes and the frequencies of the minor alleles of NAT2 SNPs in unrelated Kyrgyz and Romanian subjects and in a Caucasian and Chinese reference population are shown in Table 1. All polymorphisms in the IRCYL study populations were in Hardy-Weinberg equilibrium. The Romanians were not significantly different from Caucasians, except a higher 3′ untranslated region C allele frequency. This variant was not found in the Chinese. The Kyrgyz were closer to the Chinese than to Caucasians although the Kyrgyz allele frequencies were in between the frequencies of the two populations. The Kyrgyz differed significantly from the Romanians in four of seven SNPs (P < 0.0001) with ∼20% lower frequencies of 341C, 481C, and 803G. A higher fraction of 857A has been observed among the Kyrgyz (12.1% versus 3.2%, P < 0.0001). There were no significant differences in the frequencies of 282C>T and 590G>A (P = 0.10 and P = 0.62, respectively).

View this table:
  • View inline
  • View popup
Table 1.

Minor allele frequencies of NAT2 polymorphisms in Romanians, Kyrgyz, Caucasians, and Chinese

Sixteen Romanians (11.4%) and 47 Kyrgyz (16.2%) were homozygous for the reference sequence. A total of 54 study participants (12.6%) of either Romanian or Kyrgyz origin were estimated to carry a SNP combination not prevalent in the other study group. For all cases with more than one heterozygous SNP, many potential alleles could be related. Expected frequencies of predicted haplotypes based on coding SNPs are reported in Table 2. In analogy to the allele nomenclature [prefix asterisk (*)], we used the prefix number (#) to indicate predicted haplotypes. In both populations, the haplotypes #4, #5B, and #6A account for >80% of the predicted haplotypes. Overall, the distribution of haplotypes in the two study populations was different (permutation test, P = 0.01). We found ethnic differences in expected haplotype frequencies of >10% for #4, #5B, and #7B. The latter haplotype was mainly found in Kyrgyz subjects with an expected frequency of 11.6% based on 857A.

View this table:
  • View inline
  • View popup
Table 2.

Expected frequencies for predicted NAT2 haplotypes in the IRCYL study populations

We defined rapid acetylators for simplicity and without loss of generality as subjects carrying one or two fast alleles (*4, *11, or *12) based on the best haplotype pair for each individual. Sixty-eight Romanians (48.6%) and 188 Kyrgyz (64.8%) would be classified as rapid acetylators (data not shown). In addition, we classified the phenotype according to literature using allelic linkage information (9). No differences in the deduction of the acetylation phenotype were found between the haplotype pair-based and literature-based expert rating. However, with expert-based deduction, there remains uncertainty for >50% of the individuals because of more than one possible combination of allele pairs.

Discussion

As part of a project on environmental disasters (5), this study aimed to evaluate ethnic differences in genes involved in susceptibility to environmental agents. We described NAT2 genotypes, predicted haplotypes, and deduced phenotypes in a Central Asian (Kyrgyz) and a European (Romanian) study population. During the last decade, a high degree of variability in NAT2 alleles has been found at 15 nucleotide positions and documented in the NAT database. The SNP500Cancer Project verified 9 nucleotide positions of these 15 and an additional SNP in the 3′ flanking region. A first decision has therefore to be made on the selection of sequence variants in studies of genetic susceptibility (10). We selected all NAT2 sequence variants which were verified as polymorphic by the SNP500Cancer Project for genotyping with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Two variants (364G>A and 411A>T) turned out to be monomorphic in the Kyrgyz and Romanian study groups. No assay could be established for 191G>A, which characterizes African descent. Cascorbi and Roots (11) critically reviewed pitfalls in NAT2 genotyping and considered 282C>T and 341T>C in non-Africans to be sufficient to predict the acetylation phenotype. This has at least to be updated for 857G>A, which characterizes Asian descent.

Romanians settle in Central Europe and speak a Latin language from the time of colonization of Dacia by Roman ancestors. They were repeatedly invaded by Turkish-Mongolians. Overall, the NAT2 SNP distribution in Romanians was similar to other Caucasians with high frequencies of 481T and 803G (SNP500 database; ref. 12). Compared with the distribution of NAT2 SNPs in a group of Germans, the Romanians had a lower frequency of 341T (13). The Asian-specific SNP at site 857 is slightly more prevalent in Romanians which may reflect Mongolian invasions. The Kyrgyz settle in Central Asia, have been nomads, and speak a Turk language. They have Turkish, Scytho-Siberian, and Mongolian influences. The study population lives at Lake Issyk-Kul near China. The distribution of NAT2 SNPs in the Kyrgyz study population resembled more that of Chinese than of Caucasians although the allele frequencies were in between these populations (Perlegen database; ref. 14).

Comparing Romanians with Kyrgyz, there was a slightly larger proportion of Kyrgyz than Romanians which were homozygous carriers of the reference sequence at the investigated sites. The reference sequence was found more common in Asians than in Europeans and is even predominant in Amerindians but rare in Africans (12-17). We found a pronounced variation in four NAT2 polymorphisms which might indicate characteristics of population genetics. There was no obvious association of ethnic differences on whether a SNP results in an exchange of an amino acid or not. The mutations 282C>T and 590G>A showed no significant differences. The synonymous mutation 282C>T is common in a variety of ethnicities with low variation (SNP500 database; refs. 12, 13, 16). The nonsynonymous mutation 590G>A occurred frequently in both Caucasians and Asians but is rare in Amerindians (16). The alleles 341C, 481T, and 803G were less prevalent in Kyrgyz than in Romanians but they occur in higher frequencies in Chinese and even more in Amerindians (Perlegen database; ref. 16). Interestingly, the allele frequencies of these three variants were similar in each population: ≥40% in Caucasians, ∼20% in Kyrgyz, 6% in Chinese, and <3% in Ngawbe Indians. The allele 857A is rare in Caucasians. Its prevalence was 12% in Kyrgyz but >20% in Pacific Rim and Amerindians (16, 18).

Regarding genetic diversity, the majority of subjects in the IRCYL populations were carriers of more than one heterozygous NAT2 variant. For this group, alleles can be determined by cloning and consecutive sequencing of the single DNA strands. With SNP-based PCR methods, haplotypes can only be deduced. Thirteen haplotypes were predicted in the Kyrgyz and nine haplotypes in the Romanian study population, indicating a higher genetic diversity of the Kyrgyz. Haplotypes #4, #5B, and #6A comprised 92% of the Romanian NAT2 variants. These and haplotype #7B with the mutation at site 857 explained 95% of the Kyrgyz variants. The haplotype #5B occurred with a higher frequency in Caucasians and with a lower frequency in the Kyrgyz from Central Asia but was rare in East Asians and Amerindians (12-17).

The human NAT2 gene is supposed to be a susceptibility factor in the metabolism of xenobiotics and, in particular, in the development of bladder cancer where slow acetylators have been associated with an excess risk (19). NAT2 genotyping has been growingly employed to predict the phenotype. Slow acetylators vary by geographic region. About 50% of Caucasians are potential slow acetylators but there is a lower fraction in Asian populations (20). We also found a lower frequency of predicted slow acetylators in Kyrgyz in comparison with Romanians. In Chinese, there is an even lower fraction of slow acetylators (14, 21). Slow acetylators can be underestimated when only a few SNPs are used to predict the phenotype (10). The degree of misclassification in the prediction of the phenotype from the NAT2 genotype has been estimated to be up to 7% (13, 22-24).

In summary, we confirmed a large ethnic variation of NAT2 gene sequence. From the evolutionary perspective, this points to a selectively neutral character of the NAT2 gene (16). The variant at site 857 characterizes Asian descent. The NAT2 genotype distribution in Romanians was comparable to other Caucasians whereas Kyrgyz had minor allele frequencies in between Caucasians and East Asians. Ethnic differences in metabolic susceptibility genes indicate differences in metabolic pathways with yet unknown effect on the metabolic capacity and disease risks.

Acknowledgments

We thank the Romanian and Kyrgyz IRCYL teams for excellent field work, Tina Müller for statistical assistance, and Lucia Jorge-Nebert and Daniel Nebert for very fruitful comments.

Footnotes

  • Grant support: European Commission 5th Framework Programme for the Project “Investigation of the Risk of Cyanide in Gold Leaching on Health and Environment in Central Asia and Central Europe (IRCYL)” (contract no. ICA2-CT-2000-10036) and Bundesministerium für Bildung und Forschung (German National Genome Research Net).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted October 10, 2005.
    • Received April 13, 2005.
    • Revision received July 5, 2005.

References

  1. ↵
    Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29–42.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528–32.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005;307:1072–9.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239–48.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Ranft U, Pesch B, Vogt A. Gold Extraction in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS)—health and environmental risks. Luxembourg: International Center for Studies and Research in Biomedicine; 2005.
  6. ↵
    Weidinger S, Klopp N, Wagenpfeil S, et al. Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004;41:658–63.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–89.
    OpenUrlCrossRefPubMed
  8. ↵
    Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162–9.
    OpenUrlCrossRefPubMed
  9. ↵
    Roche Diagnostics. User manual RealArt™ NAT2 LC—PCR Kit. 2004.
  10. ↵
    Deitz AC, Rothman N, Rebbeck TR, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1543–6.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123–7.
    OpenUrlPubMed
  12. ↵
    Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996;6:423–8.
    OpenUrlCrossRefPubMed
  13. ↵
    Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581–92.
    OpenUrlPubMed
  14. ↵
    Xie HG, Xu ZH, Ou-Yang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997;7:503–14.
    OpenUrlPubMed
  15. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996;6:177–85.
    OpenUrlCrossRefPubMed
  16. ↵
    Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002;12:39–48.
    OpenUrlPubMed
  17. ↵
    Sekine A, Saito S, Iida A, et al. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J Hum Genet 2001;46:314–9.
    OpenUrlCrossRefPubMed
  18. ↵
    Lin HJ, Han Ch, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125–34.
    OpenUrlPubMed
  19. ↵
    Vineis P, Marinelli D, Autrup H, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001;10:1249–52.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115–22.
    OpenUrlCrossRefPubMed
  21. ↵
    Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000;56:689–92.
    OpenUrlCrossRefPubMed
  22. ↵
    Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683–92.
    OpenUrlAbstract/FREE Full Text
  23. O'Neil WM, Drobitch RK, MacArthur RD, et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000;10:171–82.
    OpenUrlCrossRefPubMed
  24. ↵
    Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993;2:299–303.
    OpenUrlAbstract
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 15 (1)
January 2006
Volume 15, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Variation of the N-Acetyltransferase 2 Gene in a Romanian and a Kyrgyz Population
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Variation of the N-Acetyltransferase 2 Gene in a Romanian and a Kyrgyz Population
Sylvia Rabstein, Klaus Unfried, Ulrich Ranft, Thomas Illig, Melanie Kolz, Hans-Peter Rihs, Chinara Mambetova, Mariana Vlad, Thomas Brüning and Beate Pesch
Cancer Epidemiol Biomarkers Prev January 1 2006 (15) (1) 138-141; DOI: 10.1158/1055-9965.EPI-05-0256

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Variation of the N-Acetyltransferase 2 Gene in a Romanian and a Kyrgyz Population
Sylvia Rabstein, Klaus Unfried, Ulrich Ranft, Thomas Illig, Melanie Kolz, Hans-Peter Rihs, Chinara Mambetova, Mariana Vlad, Thomas Brüning and Beate Pesch
Cancer Epidemiol Biomarkers Prev January 1 2006 (15) (1) 138-141; DOI: 10.1158/1055-9965.EPI-05-0256
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement